In this study, we established a multiplex chromogenic immunohistochemistry (IHC) assay that allowed us to quantify the five main CD4+ T cell subsets (Th1, Th2, Th17, Tfh and Treg cells), as well as CD8+ T cells, in tumor sections from 11 NSCLC patients. Here, CD8A is linked to neoplasm.